<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784119</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00612-49</org_study_id>
    <secondary_id>35RC15_8975</secondary_id>
    <nct_id>NCT02784119</nct_id>
  </id_info>
  <brief_title>APCext : Effect of Temporary Porto-caval Shunt During Liver Transplantation on Function of Liver Graft From Extended Criteria Donor</brief_title>
  <acronym>APCext</acronym>
  <official_title>APCext : Effect of Temporary Porto-caval Shunt During Liver Transplantation on Function of Liver Graft From Extended Criteria Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The success of orthotopic liver transplantation (OLT) in treatment of liver malignancy and
      endstage liver disease has led to an increase in the gap between patients on waiting-lists
      and available liver grafts. In order to compensate for this scarcity, use of liver grafts
      harvested from extended criteria donors (ECD) has become more and more frequent.

      However, these ECD grafts are known to be associated with a higher rate of primary non
      function (PNF) or early allograft dysfunction (EAD) because of a greater vulnerability to
      ischemia-reperfusion injury (IRI).

      During OLT, the clamping of the portal vein induces blood congestion in the splanchnic
      territory leading to increased gut permeability, bacterial translocation and release of
      endotoxin and pro-inflammatory cytokines at revascularisation, which exacerbate IRI.

      Realisation of a temporary porto-caval shunt (TPCS) (i.e. end to side anastomosis between the
      portal vein and infrahepatic vena cava) during the anhepatic phase, avoids splanchnic
      congestion and could therefore decrease IRI and improve liver graft function. However, TPCS
      remains poorly used as no randomised trial succeeds to show its benefit on liver function due
      to lack of power.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of early allograft dysfunction</measure>
    <time_frame>on postoperative day 7</time_frame>
    <description>defined by the presence of at least one of the following criteria:
Bilirubin level &gt; 10 mg/dL (i.e. 171 µmol/L)
International Normalized Ratio &gt; 1.6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of early allograft dysfunction</measure>
    <time_frame>within the 7 first postoperative day</time_frame>
    <description>defined by the presence of at least one of the following criteria:
• ASAT or ALAT level &gt; 2000 IU/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of primary non function</measure>
    <time_frame>within the 7 first postoperative day</time_frame>
    <description>defined by the presence of at least one of the following criteria:
Graft's death or retransplantation
Patient's death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Realisation of intra-operative transfusion</measure>
    <time_frame>during the operation</time_frame>
    <description>defined by the transfusion needs of fresh frozen plasma, red blood cell and platelet pool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of reperfusion syndrome</measure>
    <time_frame>during the 5 minutes following revascularisation</time_frame>
    <description>defined as decrease of 30% of the median arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of surgery</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver graft function</measure>
    <time_frame>within 3 months</time_frame>
    <description>evaluated by the Model for Early Allograft Function (MEAF) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a severe postoperative complication</measure>
    <time_frame>within 3 months</time_frame>
    <description>defined as a Clavien-Dindo classification &gt; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of urinary function</measure>
    <time_frame>within the first 7 days</time_frame>
    <description>defined by:
Measuring postoperative creatinine level (mg/L)
Need of renal dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft's survival</measure>
    <time_frame>at 3 months</time_frame>
    <description>defined by graft's death or retransplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's survival</measure>
    <time_frame>at 3 months</time_frame>
    <description>defined by patient's death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>temporary porto-caval shunt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no temporary porto-caval shunt</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>temporary porto-caval shunt</intervention_name>
    <arm_group_label>temporary porto-caval shunt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Candidate of liver transplantation

          -  With cirrhosis from any etiology

          -  Model For End-Stage Liver Disease (MELD) score &lt; 25

          -  Transplanted with a liver graft harvested from an extended criteria donor defined as
             presence of at least one of the following criteria:

               -  Donor age &gt; 65 years old

               -  Intensive care unit stay &gt; 7 days

               -  BMI &gt; 30

               -  Natremia &gt; 155 mmol/L

               -  Aspartate aminotransferase (ASAT) &gt; 150 IU/mL

               -  Alanine aminotransferase (ALAT) &gt; 170 IU/mL

               -  Occurrence of a cardiac arrest before graft harvesting

               -  Proven biopsy macrosteathosis &gt; 30%

          -  Non-opposition from the patient

        Non Inclusion Criteria:

          -  Fulminant hepatitis

          -  Retransplantation

          -  Combined organ transplantation (kidney, pancreas, heart, lung)

          -  Non heart beating donor

          -  Complete portal vein thrombosis on preoperative imaging finding

        Exclusion Criteria:

          -  Complete portal vein thrombosis found during procedure

          -  Split liver graft

          -  Realisation of a bilio-enteric anastomosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michel RAYAR, MD, PhD</last_name>
    <email>michel.rayar@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne GANIVET</last_name>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence CHICHE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Yves MABRUT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel RAYAR, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim BOUDJEMA, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent SULPICE, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe CAMUS, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline HOUSSEL-DEBRY, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>temporary porto-caval shunt</keyword>
  <keyword>liver graft</keyword>
  <keyword>extended criteria donor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

